
Rosina T Lis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4903052/publications.pdf Version: 2024-02-01



POSINA T LIS

#	Article	IF	CITATIONS
1	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. Journal of Urology, 2022, 208, 90-99.	0.4	2
2	Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Molecular Cancer Research, 2021, 19, 475-484.	3.4	22
3	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clinical Cancer Research, 2021, 27, 429-437.	7.0	22
4	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology, 2021, 80, 746-757.	1.9	50
5	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clinical Cancer Research, 2021, 27, 3610-3619.	7.0	17
6	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Reports, 2021, 36, 109665.	6.4	24
7	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer–A Pilot Study. Academic Radiology, 2020, 27, 1432-1439.	2.5	9
8	A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications, 2020, 11, 837.	12.8	28
9	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. European Urology, 2019, 76, 33-40.	1.9	26
10	Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i> -Defined Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 193-200.	2.5	18
11	MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 201-207.	2.5	21
12	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TMPRSS2:ERG</i> Status. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1231-1233.	2.5	2
13	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Research, 2018, 78, 4716-4730.	0.9	56
14	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	7.0	80
15	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5207-E5215.	7.1	266
16	Association of Prostate Cancer Risk Variants with <i>TMPRSS2:ERG</i> Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 745-749.	2.5	23
17	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. American Journal of Clinical Nutrition, 2016, 103, 851-860.	4.7	65
18	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 352-359.	1.9	34

Rosina T Lis

#	Article	IF	CITATIONS
19	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate, 2015, 75, 1926-1933.	2.3	8
20	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
21	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 374-381.	2.8	22
22	Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG–Positive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2027-2031.	2.5	28
23	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	1.6	220